Roxadustat is a novel agent with a distinct mechanism of action compared to erythropoiesis-
stimulating agents (ESAs) and a potentially different combination of effects on iron …

Introduction Anemia is one of the major complications of chronic kidney disease (CKD).
Erythropoiesis-stimulating agents (ESAs) have been the mainstay of renal anemia treatment …

Background: Chronic kidney disease (CKD) is a global public health problem, and anemia is
a common complication in CKD patients. Roxadustat (FG-4592) is an oral hypoxia-inducible …

Background Roxadustat, a hypoxia-inducible factor prolyl hydroxylase inhibitor, increases
hemoglobin by stimulating erythropoietin synthesis and improving iron availability through …

Aims Renal anaemia is a common complication of chronic kidney disease (CKD).
Roxadustat is the first‐in‐class oral hypoxia‐inducible factor prolyl hydroxylase inhibitor for …

Background: Roxadustat, a hypoxia-inducible factor prolyl-hydroxylase inhibitor (HIF-PHI),
has been used to treat anemia in patients with chronic kidney disease (CKD). However, its …

Introduction: Roxadustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor
approved for the treatment of anemia in Japan for patients with dialysis-dependent (DD) …

Safety concerns with erythropoietin analogues and intravenous (IV) iron for treatment of
anemia in CKD necessitate development of safer therapies. Roxadustat (FG-4592) is an …

Background: Although renal anemia has attracted widespread attention, a large proportion
of chronic kidney disease (CKD) patients with anemia still do not meet the hemoglobin (Hb) …

The effect of roxadustat (FG-4592) on individuals with chronic kidney diseases (CKD)
patients receiving or not receiving the dialysis was unclear. The aim of this study was to …